diagnosis, prognosis, and management of ahus

45
Diagnosis, Prognosis, and Management of aHUS

Upload: emmanuel-hale

Post on 31-Dec-2015

47 views

Category:

Documents


0 download

DESCRIPTION

Diagnosis, Prognosis, and Management of aHUS. Program Goals. TMA Disorders Are Now Classified by Molecular Mechanism. Hereditary Disorders Resulting in TMA. Acquired Causes of TMA. Complex Mechanisms May Contribute to Acquired TMA. Effects of Uncontrolled or Excessive Complement Activation. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Diagnosis, Prognosis, and Management of aHUS

Diagnosis, Prognosis, and Management of aHUS

Page 2: Diagnosis, Prognosis, and Management of aHUS

Program Goals

Page 3: Diagnosis, Prognosis, and Management of aHUS

TMA Disorders Are Now Classified by Molecular Mechanism

Page 4: Diagnosis, Prognosis, and Management of aHUS

Hereditary Disorders Resulting in TMA

Page 5: Diagnosis, Prognosis, and Management of aHUS

Acquired Causes of TMA

Page 6: Diagnosis, Prognosis, and Management of aHUS

Complex Mechanisms May Contribute to Acquired TMA

Page 7: Diagnosis, Prognosis, and Management of aHUS

Effects of Uncontrolled or Excessive Complement Activation

Page 8: Diagnosis, Prognosis, and Management of aHUS

Complement-Mediated TMA (aHUS) Can Affect Multiple Organs,

Tissues

Page 9: Diagnosis, Prognosis, and Management of aHUS

Extrarenal Manifestations Are Common in aHUS

Page 10: Diagnosis, Prognosis, and Management of aHUS

Keys to Diagnosing aHUS

Page 11: Diagnosis, Prognosis, and Management of aHUS

No Role for Complement-Level Testing in the Diagnosis of aHUS

Page 12: Diagnosis, Prognosis, and Management of aHUS

Challenges in Diagnosing aHUS

Page 13: Diagnosis, Prognosis, and Management of aHUS

Complement-Amplifying Conditions May Unmask aHUS

Page 14: Diagnosis, Prognosis, and Management of aHUS

Complement-Amplifying Conditions Commonly Unmask

aHUS

Page 15: Diagnosis, Prognosis, and Management of aHUS

aHUS and Complement-Amplifying Events

Page 16: Diagnosis, Prognosis, and Management of aHUS

Unmasking the Diagnosis of Complement-Mediated TMA

Page 17: Diagnosis, Prognosis, and Management of aHUS

Management Options for aHUS Have Been Limited

Page 18: Diagnosis, Prognosis, and Management of aHUS

Challenges in Evaluating PI/PE Therapy

Page 19: Diagnosis, Prognosis, and Management of aHUS

Response to Plasma Therapy for aHUS

Page 20: Diagnosis, Prognosis, and Management of aHUS

Plasma Therapy for aHUS Is Clinically Inadequate

Page 21: Diagnosis, Prognosis, and Management of aHUS

Recommendations of French Study Group for Defining PE/PI Failure

Page 22: Diagnosis, Prognosis, and Management of aHUS

Potential for Significant Morbidity/Mortality Regardless of Overt Laboratory or Clinical Signs

Page 23: Diagnosis, Prognosis, and Management of aHUS

Eculizumab: Humanized First-in-Class Anti-C5 Antibody

Page 24: Diagnosis, Prognosis, and Management of aHUS

Eculizimab Dosing Schedule: Adults

Page 25: Diagnosis, Prognosis, and Management of aHUS

Eculizumab Multinational Clinical Program Includes Broad aHUS Patient Population

Page 26: Diagnosis, Prognosis, and Management of aHUS

Eculizumab Multinational, Multicenter Clinical Program of Prospective Trials in aHUS (N = 100)

Page 27: Diagnosis, Prognosis, and Management of aHUS

Improvement in Hematologic Markers of Complement-mediated TMA Across All Studies

at 26 weeks

Page 28: Diagnosis, Prognosis, and Management of aHUS

Rapid and Sustained Improvement in Hematologic Markers of Complement-mediated TMA With or

Without Identified Genetic Mutation

Page 29: Diagnosis, Prognosis, and Management of aHUS

Early Eculizumab Therapy Associated With High Likelihood of Eliminating Dialysis

Page 30: Diagnosis, Prognosis, and Management of aHUS

Prospective Trial of Eculizumab in Adults With aHUS

Page 31: Diagnosis, Prognosis, and Management of aHUS

Safety Profile of Eculizumab in Prospective Trial of Adults With aHUS

Page 32: Diagnosis, Prognosis, and Management of aHUS

Eculizumab and Serious Meningococcal Infections

Page 33: Diagnosis, Prognosis, and Management of aHUS

Key Benefits of Eculizumab

Page 34: Diagnosis, Prognosis, and Management of aHUS

Abbreviations

Page 35: Diagnosis, Prognosis, and Management of aHUS

Abbreviations (cont)

Page 36: Diagnosis, Prognosis, and Management of aHUS

Abbreviations (cont)

Page 37: Diagnosis, Prognosis, and Management of aHUS

References

Page 38: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 39: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 40: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 41: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 42: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 43: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 44: Diagnosis, Prognosis, and Management of aHUS

References (cont)

Page 45: Diagnosis, Prognosis, and Management of aHUS

References (cont)